Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – What’s Next?

Seres Therapeutics, Inc. (NASDAQ:MCRB) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $8.13 and traded as low as $6.62. Seres Therapeutics shares last traded at $6.85, with a volume of 132,707 shares changing hands.

Analyst Upgrades and Downgrades

MCRB has been the subject of several analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Seres Therapeutics in a report on Friday, March 13th. Weiss Ratings lowered Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Finally, Wall Street Zen lowered Seres Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $22.00.

Seres Therapeutics Trading Down 4.5%

The company has a 50 day moving average price of $8.13 and a 200-day moving average price of $11.85. The company has a market cap of $66.34 million, a P/E ratio of -1.32 and a beta of 0.13.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.36 million.

Institutional Investors Weigh In On Seres Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Seres Therapeutics by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 86,142 shares of the biotechnology company’s stock worth $1,282,000 after acquiring an additional 1,160 shares during the last quarter. Invesco Ltd. grew its position in shares of Seres Therapeutics by 37.5% in the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 3,918 shares during the last quarter. State Street Corp grew its position in shares of Seres Therapeutics by 14.0% in the 4th quarter. State Street Corp now owns 33,901 shares of the biotechnology company’s stock valued at $504,000 after buying an additional 4,170 shares during the last quarter. Vontobel Holding Ltd. grew its position in shares of Seres Therapeutics by 4.8% in the 4th quarter. Vontobel Holding Ltd. now owns 103,234 shares of the biotechnology company’s stock valued at $1,536,000 after buying an additional 4,723 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of Seres Therapeutics by 2,772.6% in the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 5,157 shares during the last quarter. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.